$15.79
0.25% day before yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US4834971032
Symbol
KALV

KalVista Pharmaceuticals, Inc. Stock price

$15.79
+2.43 18.19% 1M
+4.09 34.96% 6M
+7.32 86.42% YTD
+7.03 80.25% 1Y
+10.68 209.00% 3Y
-1.73 9.87% 5Y
-34.47 68.58% 10Y
-62.05 79.71% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.04 0.25%
ISIN
US4834971032
Symbol
KALV
Industry

Key metrics

Basic
Market capitalization
$798.1m
Enterprise Value
$739.0m
Net debt
positive
Cash
$191.5m
Shares outstanding
50.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
558.1 | 13.1
EV/Sales
516.8 | 12.2
EV/FCF
negative
P/B
19.6
Financial Health
Equity Ratio
38.0%
Return on Equity
-
ROCE
-59.2%
ROIC
-1,584.0%
Debt/Equity
3.2
Financials (TTM | estimate)
Revenue
$1.4m | $60.8m
EBITDA
$-103.9m | $-200.6m
EBIT
$-104.8m | $-157.7m
Net Income
$-102.4m | $-155.5m
Free Cash Flow
$-168.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
32.9% | -
EBIT
32.6% | -
Net Income
27.8% | -
Free Cash Flow
-63.2%
Margin (TTM | estimate)
Gross
58.6%
EBITDA
-7,282.7% | -330.1%
EBIT
-7,350.6%
Net
-7,178.4% | -255.9%
Free Cash Flow
-11,814.2%
More
EPS
$-1.9
FCF per Share
$-3.3
Short interest
34.3%
Employees
150
Rev per Employee
-
Show more

Is KalVista Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

KalVista Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast:

Buy
93%
Hold
7%

Financial data from KalVista Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jul '25
+/-
%
1.43 1.43
-
100%
- Direct Costs 0.59 0.59
-
41%
0.84 0.84
-
59%
- Selling and Administrative Expenses 74 74
19% 19%
5,166%
- Research and Development Expense 32 32
66% 66%
2,222%
-104 -104
33% 33%
-7,262%
- Depreciation and Amortization 0.97 0.97
14% 14%
68%
EBIT (Operating Income) EBIT -105 -105
33% 33%
-7,330%
Net Profit -102 -102
28% 28%
-7,158%

In millions USD.

Don't miss a Thing! We will send you all news about KalVista Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

KalVista Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
4 days ago
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 ...
Neutral
Seeking Alpha
about one month ago
KalVista Pharmaceuticals, Inc. ( KALV ) Jefferies London Healthcare Conference 2025 November 19, 2025 8:30 AM EST Company Participants Benjamin Palleiko - CEO & Director Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jef...
Neutral
Seeking Alpha
about one month ago
KalVista Pharmaceuticals, Inc. ( KALV ) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Ryan Baker - Head of Investor Relations Benjamin Palleiko - CEO & Director Paul Audhya - Chief Medical Officer Nicole Sweeny - Chief Commercial Officer Brian Piekos - Chief Financial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Stacy Ku - T...
More KalVista Pharmaceuticals, Inc. News

Company Profile

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.

Head office United States
CEO Ben Palleiko
Employees 150
Founded 2004
Website www.kalvista.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today